home / stock / cmps / cmps articles
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035...
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassificat...
COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary ...
LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access t...
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials Starting this October, scientists at Imperial Colle...
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials Starting this October, scientists at Imperial Colle...
It’s still cannabis earnings season, but we’re also turning to look at some of the news from the psychedelics industry. This Trade To ...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...